Chromadex (NASDAQ:CDXC) announced its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04), Morningstar.com reports. Chromadex had a negative net margin of 82.82% and a negative return on equity of 65.33%. The company had revenue of $8.12 million for the quarter, compared to the consensus estimate of $9.00 million.
NASDAQ CDXC traded down $0.23 during trading on Thursday, reaching $3.47. 249,100 shares of the company’s stock traded hands, compared to its average volume of 338,966. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.65 and a current ratio of 4.24. The company has a market capitalization of $192.14 million, a price-to-earnings ratio of -9.91 and a beta of 1.35. Chromadex has a 12-month low of $3.19 and a 12-month high of $7.24.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its position in Chromadex by 113.4% during the 2nd quarter. Northern Trust Corp now owns 119,300 shares of the company’s stock valued at $443,000 after purchasing an additional 63,398 shares during the period. Bank of New York Mellon Corp increased its position in Chromadex by 326.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 101,106 shares of the company’s stock valued at $375,000 after purchasing an additional 77,420 shares during the period. First Republic Investment Management Inc. purchased a new position in Chromadex during the 2nd quarter valued at about $995,000. BlackRock Inc. increased its position in Chromadex by 1,629.4% during the 2nd quarter. BlackRock Inc. now owns 1,884,616 shares of the company’s stock valued at $6,992,000 after purchasing an additional 1,775,638 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Chromadex during the 2nd quarter valued at about $193,000. 16.16% of the stock is currently owned by institutional investors and hedge funds.
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.